Eli Lilly stock jumps 8% after Alzheimer’s treatment slows disease progression in major trial

by user

[ad_1]

Eli Lilly & Co.’s stock jumped 8% premarket Wednesday, after the company LLY announced positive results from a late-stage trial of its Alzheimer’s disease treatment donanemab.

The Phase 3 trial showed that donanemab “significantly slowed cognitive and functional decline” in patients with early symptomatic Alzheimer’s disease, and met its primary and all secondary endpoints, or goals.

Nearly…

[ad_2]

Source link

Related Posts

Leave a Review

This website uses cookies to improve your experience. We'll assume you're ok with this, but you can opt-out if you wish. Accept Read More

Privacy & Cookies Policy